## **Eric Florence**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5748181/publications.pdf

Version: 2024-02-01

		218592	265120
75	1,959	26	42
papers	citations	h-index	g-index
76	76	76	2860
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	PrEP user profiles, dynamics of PrEP use and followâ€up: a cohort analysis at a Belgian HIV centre (2017–2020). Journal of the International AIDS Society, 2022, 25, .	1.2	7
2	The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination. International Journal of Infectious Diseases, 2021, 105, 217-223.	1.5	6
3	Chlorhexidine mouthwash fails to eradicate oropharyngeal gonorrhea in a clinical pilot trial (MoNg). Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	0.8	4
4	Harm Reduction Practices and Needs in a Belgian Chemsex Context: Findings from a Qualitative Study. International Journal of Environmental Research and Public Health, 2020, 17, 9081.	1.2	20
5	Impact of PrEP on a STI clinic in a Belgian context: a provider's perspective. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	O
6	Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort. HIV Medicine, 2020, 21, 557-566.	1.0	6
7	Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal onâ€going viral transcription. Journal of the International AIDS Society, 2020, 23, e25453.	1.2	33
8	Should We Screen HIV-Positive Migrants for Strongyloidiasis?. Pathogens, 2020, 9, 388.	1.2	2
9	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials, 2019, 20, 361.	0.7	31
10	Superimposing incident sexually transmitted infections on HIV phylogram to investigate possible misclassification of men who have sex with men as heterosexuals in a cohort in Antwerp, Belgium. International Journal of STD and AIDS, 2019, 30, 486-495.	0.5	0
11	High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports. Sexual Health, 2019, 16, 80.	0.4	19
12	Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 269-277.	3.7	39
13	Longâ€ŧerm effectiveness of recommended boosted protease inhibitorâ€based antiretroviral therapy in Europe. HIV Medicine, 2018, 19, 324-338.	1.0	4
14	HIV testing for key populations in Europe: A decade of technological innovation and patient empowerment complement the role of health care professionals. HIV Medicine, 2018, 19, 71-76.	1.0	5
15	Repeat syphilis has a different immune response compared with initial syphilis: an analysis of biomarker kinetics in two cohorts. Sexually Transmitted Infections, 2018, 94, 180-186.	0.8	18
16	Increases in condomless chemsex associated with HIV acquisition in MSM but not heterosexuals attending a HIV testing center in Antwerp, Belgium. AIDS Research and Therapy, 2018, 15, 14.	0.7	35
17	CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients. Cytometry Part B - Clinical Cytometry, 2017, 92, 476-484.	0.7	9
18	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases, 2017, 64, 1413-1421.	2.9	66

#	Article	IF	CITATIONS
19	Sexual Behavior and Sexually Transmitted Infections Among Swingers: Results From an Online Survey in Belgium. Journal of Sex and Marital Therapy, 2017, 43, 709-719.	1.0	16
20	A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. PLoS ONE, 2017, 12, e0183530.	1.1	23
21	Evaluation of the intercept oral specimen collection device with HIV assays versus paired serum/plasma specimens. Journal of Virological Methods, 2016, 234, 164-168.	1.0	4
22	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. Lancet Respiratory Medicine, the, 2016, 4, 980-989.	5.2	38
23	Late presentation to HIV testing is overestimated when based on the consensus definition. HIV Medicine, 2016, 17, 231-234.	1.0	20
24	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	1.3	22
25	Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants. BMC Infectious Diseases, 2015, 15, 496.	1.3	26
26	Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 585-593.	0.9	50
27	Swab2know: An HIV-Testing Strategy Using Oral Fluid Samples and Online Communication of Test Results for Men Who Have Sex With Men in Belgium. Journal of Medical Internet Research, 2015, 17, e213.	2.1	40
28	Factors associated with the continuum of care of HIV-infected patients in Belgium. Journal of the International AIDS Society, 2014, 17, 19534.	1.2	17
29	Use of rapid HIV testing in a low threshold centre in Antwerp, Belgium, 2007–2012. International Journal of STD and AIDS, 2014, 25, 936-942.	0.5	13
30	Vitros 5600 Syphilis TPA Assay. Sexually Transmitted Diseases, 2014, 41, 680-683.	0.8	3
31	Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials. Clinical Infectious Diseases, 2014, 59, 425-434.	2.9	49
32	What is the significance of posttreatment control of HIV infection vis-Ã-vis functional cure?. Aids, 2014, 28, 603-605.	1.0	5
33	Deteriorating renal function and clinical outcomes in HIV-positive persons. Aids, 2014, 28, 727-737.	1.0	25
34	Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium – 1992 to 2012. Eurosurveillance, 2014, 19, 20958.	3.9	46
35	Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. Nanomedicine, 2013, 8, 77-87.	1.7	14
36	Using conventional HIV tests on oral fluid. Journal of Virological Methods, 2013, 194, 46-51.	1.0	25

#	Article	IF	CITATIONS
37	INCIDENCE OF HCV AND SEXUALLY TRANSMITTED DISEASES AMONG HIV POSITIVE MSM IN ANTWERP, BELGIUM, 2001-2011. Acta Clinica Belgica, 2013, 68, 421-426.	0.5	10
38	Validation of Clinical Scores for Risk Assessment. Clinical Infectious Diseases, 2012, 54, 1520-1521.	2.9	8
39	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Aids, 2012, 26, F1-F12.	1.0	88
40	Immune and Viral Correlates of "Secondary Viral Control―after Treatment Interruption in Chronically HIV-1 Infected Patients. PLoS ONE, 2012, 7, e37792.	1.1	43
41	Monocytes Contribute to Differential Immune Pressure on R5 versus X4 HIV through the Adipocytokine Visfatin/NAMPT. PLoS ONE, 2012, 7, e35074.	1.1	34
42	Voluntary outreach counselling and testing for HIV and STI among men who have sex with men in Antwerp. Acta Clinica Belgica, 2012, 67, 172-6.	0.5	8
43	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. HIV Clinical Trials, 2011, 12, 109-117.	2.0	29
44	Control of viral replication after cessation of HAART. AIDS Research and Therapy, 2011, 8, 6.	0.7	10
45	Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. Journal of Antimicrobial Chemotherapy, 2011, 66, 265-272.	1.3	22
46	PREVALENCE OF CHRONIC RENAL FAILURE STAGE 3 OR MORE IN HIV-INFECTED PATIENTS IN ANTWERP: AN OBSERVATIONAL STUDY. Acta Clinica Belgica, 2010, 65, 392-398.	0.5	4
47	HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Research and Therapy, 2010, 7, 4.	0.7	36
48	Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen. AIDS Research and Therapy, 2010, 7, 40.	0.7	50
49	Prevalence of chronic renal failure stage 3 or more in HIVâ€infected patients in Antwerp: an observational study. Journal of the International AIDS Society, 2010, 13, P89.	1.2	1
50	Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. International Journal of STD and AIDS, 2010, 21, 765-769.	0.5	11
51	HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. International Journal of STD and AIDS, 2010, 21, 224-225.	0.5	6
52	Transcriptome analysis of monocyte-HIV interactions. Retrovirology, 2010, 7, 53.	0.9	52
53	Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001–2009. Eurosurveillance, 2010, 15, .	3.9	65
54	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. Journal of Antimicrobial Chemotherapy, 2009, 64, 1341-1344.	1.3	6

#	Article	IF	CITATIONS
55	Efficient In Vitro Expansion of Human Immunodeficiency Virus (HIV)-Specific T-Cell Responses by <i>gag &lt; /i &gt; mRNA-Electroporated Dendritic Cells from Treated and Untreated HIV Type 1-Infected Individuals. Journal of Virology, 2008, 82, 3561-3573.</i>	1.5	26
56	Fever After a Stay in the Tropics: Clinical Spectrum and Outcome in HIV-Infected Travelers and Migrants. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 547-552.	0.9	21
57	HIV and Syphilis: When to Perform a Lumbar Puncture. Sexually Transmitted Diseases, 2007, 34, 141-144.	0.8	124
58	Sexual dysfunction in HIV-positive men is multi-factorial: A study of prevalence and associated factors. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 955-965.	0.6	90
59	Therapeutic Immunization with Dendritic Cells Loaded with Heatâ€Inactivated Autologous HIVâ€1 in Patients with Chronic HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 1680-1685.	1.9	147
60	Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption. Clinical Infectious Diseases, 2004, 39, 569-574.	2.9	23
61	Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre. International Journal of STD and AIDS, 2004, 15, 523-528.	0.5	1
62	The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. International Journal of STD and AIDS, 2004, 15, 538-542.	0.5	21
63	Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 550-557.	0.6	59
64	Multiple Tuberculous Brain Abscesses in an HIV-Infected Patient Successfully Treated with HAART and Antituberculous Treatment. Infection, 2003, 31, 118-120.	2.3	11
65	The use of complementary and alternative medicine by persons with HIV infection in Europe. International Journal of STD and AIDS, 2003, 14, 672-674.	0.5	32
66	Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?. International Journal of STD and AIDS, 2003, 14, 1-5.	0.5	2
67	HIV and sexual dysfunction. International Journal of STD and AIDS, 2003, 14, 69-69.	0.5	1
68	Self-reported signs of lipodystrophy by persons living with HIV infection. International Journal of STD and AIDS, 2002, 13, 393-398.	0.5	6
69	Rheumatological complications associated with the use of indinavir and other protease inhibitors. Annals of the Rheumatic Diseases, 2002, 61, 82-84.	0.5	48
70	PATIENTS WITH HIV INFECTION AND FEVER: A DIAGNOSTIC APPROACH. Acta Clinica Belgica, 2002, 57, 184-190.	0.5	12
71	Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. Aids, 2001, 15, 1019-1023.	1.0	98
72	Antiretroviral treatments used among adults with HIV infection in Europe. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2001, 13, 5-14.	0.6	4

## ERIC FLORENCE

#	Article	IF	CITATIONS
73	Safe and Effective Use of Combination Antiretroviral Treatment. Acta Clinica Belgica, 1999, 54, 55-60.	0.5	3
74	Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, The, 1998, 351, 1813.	6.3	4
75	Self-Control as Conceptual Framework to Understand and Support People Who Use Drugs During Sex. Frontiers in Public Health, 0, 10, .	1.3	2